Literature DB >> 21167432

[Pathology of cholangiocarcinoma].

Nathalie Guedj1, Pierre Bedossa, Valérie Paradis.   

Abstract

Cholangiocarcinomas (CC) are tumors that arise from the epithelial cell of the biliary tract. They represent the second most frequent primitive liver malignancy after hepatocellular carcinoma. Recent epidemiological data show an increase incidence of CC independently of the increased incidence of cirrhosis. According to their location in the biliary tract, we distinguish intrahepatic, hilar (Klastkin tumors) and extrahepatic CC. In literature, confusion exists around hilar CC that are included, according series, to intrahepatic or extrahepatic CC. However, hilar CC share common clinical, morphological and therapeutic features with extrahepatic CC. So, OMS classification of digestive tumors defined two groups of CC: intrahepatic or peripheral CC which develop from small intrahepatic biliary duct beyond the second segmentation, and extrahepatic CC comprising hilar CC and tumors from common hepatic bile duct. In this chapter, we will describe the different gross features and histological characteristic of CC and will detail the major histopronostic criteria of these tumors.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167432     DOI: 10.1016/j.annpat.2010.10.004

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  3 in total

1.  CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.

Authors:  Rosa Coelho; Marco Silva; Eduardo Rodrigues-Pinto; Hélder Cardoso; Susana Lopes; Pedro Pereira; Filipe Vilas-Boas; João Santos-Antunes; José Costa-Maia; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2017-02-23

2.  MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma.

Authors:  Luigi Grazioli; Lucio Olivetti; Giancarlo Mazza; Maria Pia Bondioni
Journal:  Int J Hepatol       Date:  2013-03-27

3.  FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.

Authors:  Jan Hrudka; Zuzana Prouzová; Katarína Mydlíková; Kristína Jedličková; Michal Holešta; Adam Whitley; Lukáš Havlůj
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.